Abstract
ObjectiveThis study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy.MethodsInitially, 20 patients with HCC were screened and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have